Novartis announces pelacarsen Lp(a)HORIZON Phase 3 topline: primary endpoint missed
Novartis announced pelacarsen Phase 3 Lp(a)HORIZON topline results. The study did not meet its primary endpoint to reduce the risk of cardiovascular events, a composite including cardiovascular death and non-fatal myo…